What Happened to Wegovy?
Wegovy, a semaglutide-based GLP-1 receptor agonist developed by Novo Nordisk, revolutionized obesity treatment following its injectable FDA approval in 2021. Despite initial widespread supply shortages, it has expanded its indications to include cardiovascular risk reduction and MASH treatment, and notably launched an oral pill version in the U.S. in early 2026, intensifying competition in the rapidly growing weight-loss drug market.
Quick Answer
Wegovy, originally an injectable medication for chronic weight management, has seen significant developments up to March 2026. It gained FDA approval for reducing cardiovascular risks in March 2024 and for treating MASH in August 2025. A major turning point was the FDA approval of an oral pill version in December 2025, which launched in the U.S. in January 2026 at a more competitive price point. The European Commission also approved a higher injectable dose in February 2026, while Novo Nordisk has recently cut prices for its GLP-1 products amidst fierce competition and ongoing legal challenges regarding side effects.
📊Key Facts
📅Complete Timeline14 events
Semaglutide First Approved for Type 2 Diabetes
Semaglutide, the active ingredient in Wegovy, received its initial FDA approval under the brand name Ozempic for the treatment of Type 2 Diabetes.
FDA Approves Injectable Wegovy for Chronic Weight Management
The U.S. FDA approved injectable Wegovy (semaglutide 2.4 mg) for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity, marking a significant advancement in obesity treatment.
EMA Grants Marketing Authorization for Injectable Wegovy in EU
The European Medicines Agency (EMA) granted marketing authorization for injectable Wegovy, making it available for use across the European Union for weight management.
Wegovy Placed on FDA Drug Shortage List
Due to overwhelming demand and manufacturing limitations, Wegovy was added to the FDA's drug shortage list, leading to significant access issues for patients.
FDA Approves Wegovy for Cardiovascular Risk Reduction
The FDA approved an expanded indication for injectable Wegovy to reduce the risk of major adverse cardiovascular events (cardiovascular death, heart attack, and stroke) in adults with cardiovascular disease and obesity or overweight.
FDA Declares End to Injectable Wegovy Shortage
The FDA announced that the shortages of injectable Wegovy and Ozempic had been resolved, indicating that Novo Nordisk was able to meet current and projected demand.
FDA Expands Wegovy Indication for MASH Treatment
The FDA expanded Wegovy's indication to include the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
FDA Approves Oral Wegovy Pill
The FDA approved the first-ever once-daily oral formulation of Wegovy (semaglutide 25 mg) for chronic weight management and cardiovascular risk reduction in adults, based on positive OASIS 4 trial results.
Oral Wegovy Pill Launches in U.S.
Novo Nordisk officially launched the Wegovy pill in the U.S., making the oral GLP-1 weight-loss medicine broadly available at a competitive starting price of $149/month for self-pay patients.
Novo Nordisk Forecasts Revenue Drop Amid Competition
Novo Nordisk predicted a sharp decline in 2026 revenues, citing increased competition from rivals like Eli Lilly, pricing pressures, and the eventual loss of patent protections.
EU Approves Higher Injectable Wegovy Dose
The European Commission approved a new 7.2 mg once-weekly maintenance dose of injectable Wegovy for adults with obesity in the EU, offering another option for greater weight loss.
Research Questions Oral Wegovy Ingredient's Long-Term Effects
Research from Adelaide University suggested that SNAC, an ingredient in oral semaglutide that aids absorption, might have biological effects beyond its intended role, potentially impacting gut bacteria and inflammatory markers.
Novo Nordisk Cuts GLP-1 Product Prices
Novo Nordisk announced price cuts for its GLP-1 products, including Wegovy, setting a uniform price of $675 a month across the board in response to market competition and payer demands.
Ongoing Litigation for GLP-1 Side Effects
Federal multidistrict litigation continues against manufacturers of GLP-1 drugs, including Wegovy, addressing claims of serious gastrointestinal injuries like gastroparesis and vision loss.
🔍Deep Dive Analysis
Wegovy, a brand name for semaglutide, emerged as a groundbreaking medication for chronic weight management, receiving U.S. Food and Drug Administration (FDA) approval for its injectable form on June 4, 2021. Developed by Novo Nordisk, it functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking a natural hormone to regulate appetite, slow gastric emptying, and improve blood sugar control, leading to significant weight loss. Its efficacy, demonstrated by an average weight loss of approximately 15% in clinical trials, quickly led to immense demand.
The rapid and overwhelming demand for Wegovy, alongside its sister drug Ozempic (also semaglutide, for Type 2 diabetes), resulted in persistent supply shortages starting in March 2022, which significantly hampered patient access. This period saw compounding pharmacies stepping in, though Novo Nordisk issued warnings about unapproved compounded versions. A key turning point came on March 8, 2024, when the FDA expanded Wegovy's indication to include reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight, based on the landmark SELECT trial. This expanded label underscored the drug's broader health benefits beyond just weight loss. By February 21, 2025, the FDA declared the injectable Wegovy shortage resolved, indicating Novo Nordisk's increased manufacturing capacity could meet demand.
Further expanding its therapeutic reach, Wegovy received FDA approval in August 2025 for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH, with moderate to advanced liver fibrosis. The most significant recent development, however, was the FDA's approval of a once-daily oral formulation of Wegovy (the 'Wegovy pill') on December 22, 2025. This oral version, which showed comparable efficacy to the injectable in trials like OASIS 4 with an average weight loss of 16.6% (with adherence), launched in the U.S. in early January 2026. The introduction of a pill form aimed to address patient preferences, eliminate the need for injections, and potentially expand accessibility.
As of early 2026, the landscape for Wegovy is marked by intensified competition and strategic pricing adjustments. Novo Nordisk launched the oral Wegovy at a lower starting self-pay price of $149 per month in the U.S., aiming to gain market share against rivals like Eli Lilly's Zepbound and its upcoming oral GLP-1, orforglipron. In February 2026, the European Commission approved a new, higher 7.2 mg once-weekly maintenance dose for injectable Wegovy in the EU, offering greater weight loss potential. However, Novo Nordisk forecasted a sharp drop in 2026 revenues, attributing it to pricing pressures, increased competition, and the eventual loss of patent protections. In March 2026, Novo Nordisk announced price cuts for its GLP-1 products, including Wegovy, setting a uniform price of $675 a month across the board, further signaling a burgeoning price war in the GLP-1 market.
Despite its successes, Wegovy faces ongoing scrutiny. Research published in March 2026 from Adelaide University raised questions about salcaprozate sodium (SNAC), an ingredient in oral semaglutide that aids absorption, suggesting it might have biological effects beyond its intended role, impacting gut bacteria and inflammatory markers in animal studies. Furthermore, the company is navigating significant legal challenges, with federal multidistrict litigation ongoing as of March 2026, addressing claims of gastrointestinal injuries like gastroparesis and vision loss across GLP-1 drugs. The long-term affordability and accessibility of Wegovy, particularly in lower-income countries where manufacturing costs could be as low as $3 a month, remain a global health discussion as patents are still years from expiring in major markets.
What If...?
Explore alternate histories. What if Wegovy made different choices?